PALO ALTO, Calif., Jan. 2, 2018 /PRNewswire/ —CTIC Capital today announced that Randy, W. Schekman, Nobel laureate, the 2013 Nobel Prize in Physiology or Medicine, Professor of Molecular and Cell Biology, University of California, Berkeley, will serve as the keynote for its second annual CTIC Capital Cross-Border Healthcare Investment Summit, co-hosted by BioCentury. Convening more than 150 Chinese healthcare investors, the Summit will be held on Sunday, January 7, 2018, at the Hyatt Regency San Francisco. Dr. Schekman’s presentation is entitled, “Prospects for Use of Exosomes in Cancer Diagnosis and Treatment.” http://www.cticcapital.com/2018-healthcare-investment-summit/
“The 2018 CTIC Capital Cross-Border Healthcare Investment Summit serves as the definitive place for Chinese and US investors and executives to network, collaborate and build partnerships,” said Yanhong Lin, Founder and Managing Partner, CTIC Capital. “Building on the tremendous success of last year’s inaugural Summit which was the most well-attended event during the JP Morgan Healthcare Conference by top Chinese investors, this year’s conference has attracted the top Chinese healthcare investment firms and pharmaceutical companies, and our Chinese investment speakers are the most sought-after investors in China. Our agenda is jam-packed and we couldn’t be more thrilled.”
Attendees at the event will participate in motivating keynote and panel discussions from an impressive array of speakers, partnering opportunities with a 1:1 ratio between investors and company executives, and startup competitions. New features of this year’s Summit include:
Extended time for one-on-one partnering systems mobile app that facilitates communications between investors and company executives
Each of the six companies out of hundreds of applications will present and be evaluated by one investor with the goal of providing insights into the industries and elements to be a successful investment project from Chinese investors’ perspective
“The US is the most innovative country for healthcare technologies and I am most excited about the opportunity to meet company executives and potential partners at CTIC Capital’s event,” commented Xiaobao Lu, Partner, Sequoia Capital China.
Partial confirmed participating investors include: 3E Bioventures, AbbVie, Ally Bridge Group, Bayer, Berry Genomics, BioSciKin, Button Capital, Canaan, CD Capital, CDH Venture, CLI Ventures, Cloudstone Ventures, CRV, Cybernaut Investment Group, daVinci Capital Group, Decheng Capital, Delos Capital, Dian Diagnostics, DigitalDx Ventures, Flagship Pioneering, Fosun Healthcare Holdings, Fosun Pharma, FountainVest Partners, Foxconn Healthcare Group, GF Investments, GF Xinde Investment Company, Good Health Capital, Hemi Ventures, Hermed Capital, Hopu Capital, IDGVC, InterWest Partners, Khosla Ventures, KPCB China, LDV Partners, Legend Capital, Life Science Angels (LSA), Lilly Asia Ventures, Lumira Capital, Lyfe Capital, Marathon venture partners, Milestone Capital, Morningside Ventures, Northern Light Venture Capital, Ping An Bank, Ping An Ventures, Qilu Pharmaceuticals, Qiming Venture, Sangel Capital, SANOFI, SanPower Group, Sequoia Capital China, Shanghai Jianxin Capital Management, Silicon Valley Future Capital, Teng Yue Partners, Tianjin Ren Ai Group, Top Tier Capital Partners, Virtus Inspire Ventures, VMS Investment Group, Wondfo, YF Capital, Yimei Capital, Zhejiang Grand Health Industry Equity Investment Fund.
Event sponsors include:
Converge Minds, H. C. Wainwright & Co., Wilson Sonsini Goodrich & Rosati, Sequoia Capital China, East West Bank, PitchBook, LYFE Capital, Sangel Capital, Moss Adams, and China-US Program for Entrepreneurship and Innovation.
About CTIC Capital
CTIC Capital is a Silicon Valley based boutique private equity consulting firm focusing on healthcare, Internet technology and alternative energy. Leveraging our trans-pacific network and local expertise, we help US and Chinese enterprises in funding, M&A and strategic partnership development. Our goal is to be the trusted partner for US and Chinese enterprises in their cross-border investments and business expansion. Visit www.cticcapital.com for more information.
云集150多位中国医疗投资者的第二届年度 CTIC Capital 跨境医疗投资峰会将于2018年1月7日（周日）在旧金山凯悦酒店举行。届时，2013年诺贝尔理学与医学奖得主、加州大学伯克利分校分子与细胞生物学教授兰迪-谢克曼将发表主题演讲。
加州帕洛阿尔托2018年1月4日电 /美通社/ — CTIC Capital 今天宣布，在其与 BioCentury 联合举办的第二届年度 CTIC Capital 跨境医疗投资峰会 (CTIC Capital Cross-Border Healthcare Investment Summit) 上，2013年诺贝尔理学与医学奖 (Nobel Prize in Physiology or Medicine) 得主、加州大学伯克利分校 (University of California, Berkeley) 分子与细胞生物学教授兰迪-谢克曼 (Randy, W. Schekman) 将发表主题演讲。该峰会云集150多位中国医疗投资者，将于2018年1月7日（周日）在旧金山凯悦酒店 (Hyatt Regency San Francisco) 举行。谢克曼博士的演讲题为“关于在癌症诊断与治疗中使用外来体的前景”(Prospects for Use of Exosomes in Cancer Diagnosis and Treatment)。本次峰会的网址为：http://www.cticcapital.com/2018-healthcare-investment-summit/。
CTIC Capital 创始人兼执行合伙人 Yanhong Lin 表示：“2018年 CTIC Capital 跨境医疗投资峰会将成为中美投资者与高管开展交流、合作并建立业务关系的最终舞台。以去年首届峰会 — 摩根大通医疗保健大会 (JP Morgan Healthcare Conference) 期间中国投资者参与最多的活动 — 取得巨大成功为基础，今年的峰会已经吸引了顶尖的中国医疗投资公司和制药公司，并且我们的中国投资演讲者是中国最受欢迎的投资者。我们的日程排满，我们为此激动不已。”
红杉资本中国基金 (Sequoia Capital China) 合伙人 Xiaobao Lu 在对此评论时说：“美国是医疗技术最具创新的国家，我很高兴能够有机会在 CTIC Capital 举办的活动上结识公司高管和潜在合作伙伴。”
确认参与的部分投资者包括：本草资本、艾伯维 (AbbVie)、汇桥资本集团 (Ally Bridge Group)、拜耳 (Bayer)、贝瑞基因、百家汇、巴特恩资本 (Button Capital)、迦南、创道资本、鼎晖创投、CLI Ventures、Cloudstone Ventures、查尔斯河风险投资公司 (CRV)、赛伯乐投资集团、daVinci Capital Group、德诚资本、Delos Capital、迪安诊断、DigitalDx Ventures、Flagship Pioneering、复星集团健康控股、复星医药、方源资本、富士康健康业务集团 (Foxconn Healthcare Group)、广发投资、广发信德投资管理有限公司、Good Health Capital、Hemi Ventures(和米资本)、通德资本、厚朴资本、IDGVC、InterWest Partners、Khosla Ventures（科斯拉风险投资公司）、凯鹏华盈 (KPCB China)、复盛创投、君联资本、Life Science Angels (LSA)、礼来亚洲基金 (Lilly Asia Ventures)、Lumira Capital、济峰资本、远毅资本、麦顿投资、晨兴创投、北极光创投、平安银行、平安创新投资基金、齐鲁制药、启明创投、仙瞳资本、赛诺菲 (SANOFI)、三胞集团、红杉资本中国基金、上海建信股权投资管理公司、Silicon Valley Future Capital、Teng Yue Partners（腾跃）、天津市仁爱集团、Top Tier Capital Partners、弘励创投、VMS Investment Group（鼎珮投资集团）、万孚生物、云锋基金、熠美投资 (Yimei Capital) 和浙江大健康产业股权投资基金。
Converge Minds、H. C. Wainwright & Co.、美国威尔逊-桑西尼-古奇-罗沙迪律师事务所 (Wilson Sonsini Goodrich & Rosati)、红杉资本中国基金、华美银行 (East West Bank)、PitchBook、济峰资本、仙瞳资本、Moss Adams（莫斯-亚当斯会计师事务所）和 China-US Program for Entrepreneurship and Innovation（中美创业与创新计划）。
CTIC Capital 简介
CTIC Capital 是一家总部位于硅谷的精品私募股权咨询公司，主要关注于医疗、互联网技术和替代型能源。依托我们的跨太平洋网络和本地专长，我们能够为中美企业在融资、并购和战略合作开发方面提供帮助。我们的目标是成为中美企业在其跨境投资和业务拓展方面值得信赖的合作伙伴。详情请访问：www.cticcapital.com。
“The 2018 CTIC Capital Cross-Border Healthcare Investment Summit serves as the definitive place for Chinese and US investors and executives to network, collaborate and build partnerships,” said Yanhong Lin, Founder and Managing Partner, CTIC Capital. “Building on the tremendous success of last year’s inaugural Summit which was the most well-attended event during JPM by top Chinese investors, this year’s conference has attracted the top Chinese healthcare investment firms and pharmaceutical companies.”
CTIC Capital screened several hundred companies along key criteria including strength of management team, strength of investors and advisors, clear competitive edge technologically, scale of market opportunities for products including their relevance in China, stage of the company and overall attractiveness to Chinese investors.
“Epic Sciences is proud to be selected as one of the six presenting companies at the 2018 CTIC Capital Cross-Border China-US Healthcare Investment Summit,” said Murali Prahalad, President & CEO of Epic. “Given the thoughtful criteria and rigorous vetting process, Epic’s selection is a significant recognition of our progress and differentiation on a number of fronts. Such progress includes improvements to our computer vision and machine learning based rare cell detection platform. This technology has been used to develop a portfolio of blood-based tests of drug response in cancer that are clinically proven, predictive and personalized. The most advanced of these tests is Epic’s AR-V7 Test – which has demonstrated predictive clinical utility of drug response in metastatic prostate cancer. The test will be launched in the United States through a partnership with Genomic Health under the brand name Oncotype DX® AR-V7 Nucleus Detect™. The AR-V7 test and other tests in our portfolio have the potential to extend life and improve healthcare economics worldwide. These tests have special relevance for markets like China where rapid industrialization and changing demographics have made improvements in cancer care a national priority.”
About Epic Sciences Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells. Epic Sciences No Cell Left Behind® technology helps match patients to therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DX® AR-V7 Nucleus DetectTMtest, which helps with therapeutic decisions between taxane chemotherapy or androgen-directed therapeutics in metastatic castrate-resistant prostate cancer. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences’ goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices. Epic Sciences is headquartered in San Diego.
Despite tough talk by President-elect Donald Trump about a possible trade war, Chinese investors are hungry for U.S. biotech and they’ve got money to spend.
In the latest purchase following a record 2016 for Chinese health-care takeovers, Nanjing-based Sanpower Group Co., said Tuesday it would buy a cancer treatment business from Valeant Pharmaceuticals International Inc. for $820 million.
Sanpower’s interest is far from unique: Chinese venture capitalists and individual investors are looking as well. Last Sunday morning, in a hotel ballroom a short hop from the San Francisco airport, about 250 jet-lagged potential dealmakers and American biotech executives could be heard chatting in Mandarin and English. They were attending a get-together hosted by boutique investment firm CTIC Capital, hoping to forge alliances before the start of the industry’s biggest annual gathering, the J.P. Morgan Healthcare Conference, at the Westin St. Francis in San Francisco, which runs this week.
China has a “huge pile of money’’ and a lot of new venture capital firms, but a limited number of homegrown drug startups to invest in, said Kevin Chen, a partner at the China Fund of Menlo Park, California-based Sequoia Capital. The fund, which spends about a quarter of its $3 billion under management on health care, last year started founding U.S.-based startups with Chinese ties, helping bridge the gap for investors.
U.S. investors are beginning to notice. The J.P. Morgan conference has an entire track dedicated to China-based health-care companies at the conference. And last year, Chinese firms announced or completed about $8 billion in cross-border acquisitions, according to data compiled by Bloomberg.
“The gate is open and it won’t be closed again,” said Lan Huang, chief executive officer of BeyondSpring Pharmaceuticals Inc., a maker of cancer drugs with headquarters in New York and offices in Dalian, China. Her company, which plans to go public, has been meeting with investors from both countries.
The conference comes at a pivotal moment for the two nations. Trump’s rhetoric toward China has some investors worrying about a chilling effect on business. He has promised tariffs on Chinese goods, and China has said it’s prepared to step up its scrutiny of U.S. companies.
“If there’s no clear sign that it’s safe to invest in the U.S. and that innovation will import to China, that’s going to hurt investors,’’ said Jennifer Hu, a partner at China-based Qiming Ventures Partners. “They could go to Australia or Canada for that innovation instead.’’
Qiming, which spends about 40 percent of its $2.7 billion in funds on health care, is currently raising money for its first fund to be dedicated to U.S. health investments. Up to now, Qiming had focused its investments on Chinese companies.
Yet unless there’s “dramatic change” in U.S. policy, Sequoia’s Chen sees Chinese investors continuing to push money toward U.S. biotechs.
Out of Reach
Reasons include a shortage of Chinese companies whose financials pencil out. Many that have gone public are “unicorns” worth more than $1 billion — valuations that may be out of reach, said Yanhong Lin, founder and managing partner of CTIC, which is based in Palo Alto, California, and has offices in Shanghai and Nanjing.
While Chinese regulators are becoming more amenable to approving homegrown drugs, the U.S. is still perceived as the place to go for growth.
“The U.S. still represents the highest technology,” said Huang, the BeyondSpring CEO. As Chinese investors “increasingly are trying to think globally, this meeting is their opportunity.”